Dr. Sastry Srikonda

Dr. Sastry has been in the Biopharmaceutical industry for over 25 years with proven drug development, clinical strategic development, and regulatory expertise. He was a development leader for several new drugs that are approved by FDA and currently on the US market for the treatments of cardiovascular (Product: Renexa), Restless Legs Syndrome (Product: Horizant), pulmonary disease (Products: Esbriet in the US, EU, and ROW) and other areas. He worked on peptide vaccine products to treat metastatic breast cancer, Acute Myeloid Leukemia and Ovarian Cancer as Vice President of development. He currently provides scientific and development guidance and leadership advice under his company SM Expert LLC on various biological products including Perlican Domain Proteins and Kinase inhibitors in the therapy of stroke and other angiogenesis areas. He held several key positions from Scientist to Vice President at various organizations including Bristol Myers Squibb, Yamanouchi, Xenoport, Intermune, and Galena Biopharma with increasing responsibilities at various product development stages. Dr. Sastry holds a Bachelor and Masters in of Pharmacy from Kakatiya University, Warangal, India, and Ph.D. in Pharmaceutics from the University of Louisiana, Monroe. He is also a RAPS certification holder in US drug development regulatory affairs. He is well-published and holds several patents and, also a founding member of a start-up organization in India.

Free ebooks Library Z-Library project